ARK Invest's position in NTRA, updated every trading day. Data as of 2026-11-12.
| Fund | Shares | Value | Weight | Rank |
|---|---|---|---|---|
| ARKK | 288,418 | $93.1M | 1.28% | #28 |
| ARKG | 281,556 | $90.9M | 4.60% | #8 |
| Trade day | Fund | Side | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-11-06 | ARKK | Buy | Added | 46,389 | $14.4M |
| 2026-11-06 | ARKG | Buy | Added | 15,572 | $4.8M |
| 2026-10-08 | ARKK | Sell | Trimmed | 19,921 | $7.8M |
| 2026-09-14 | ARKK | Sell | Trimmed | 7,805 | $2.7M |
| 2026-08-17 | ARKK | Sell | Trimmed | 20,308 | $6.4M |
| 2026-08-04 | ARKK | Sell | Trimmed | 3,189 | $878K |
| 2026-08-03 | ARKK | Sell | Trimmed | 18,060 | $4.9M |
| 2026-07-29 | ARKK | Sell | Trimmed | 4,495 | $1.1M |
| 2026-07-28 | ARKK | Sell | Trimmed | 6,771 | $1.7M |
| 2026-07-20 | ARKK | Sell | Trimmed | 11,231 | $2.9M |
| 2026-07-16 | ARKK | Sell | Trimmed | 19,375 | $5.2M |
| 2026-07-09 | ARKK | Sell | Trimmed | 21,540 | $6.1M |
Natera, Inc., a diagnostics company, engages in the development and commercialization of molecular testing services worldwide. It offers Signatera, a personalized ctDNA blood test for MRD assessment, early recurrence monitoring, and evaluation of treatment response in patients previously diagnosed with cancer; Latitude, a blood-based MRD test for colorectal cancer; Altera, a tissue based comprehensive genomic…
See NTRA's full ARK history since 2024, ARK's estimated cost basis, the conviction score and buy/sell alerts.
Open NTRA on FundWake →Data comes from ARK Invest's public daily holdings and trade files. FundWake is not affiliated with ARK Invest. Nothing here is investment advice.